Teva Seeks To Revoke Astellas' Incontinence Drug Patent

Law360, London (December 18, 2020, 7:52 PM GMT) -- Israeli generics giant Teva Pharmaceuticals has sued Astellas Pharma in England, seeking to invalidate the Japanese drugmaker's patent for treating urinary concerns.

In its High Court filing, Teva raised a host of objections to the patent, arguing that it is obvious and inadequately described. The generic drugmaker also said that Astellas' patent says it covers a medicine for treating or preventing pollakiuria and urinary incontinence, while also claiming that its a remedy for use in the treatment of overactive bladder.

"These are not the same invention," Teva said in its newly public filing.

The "priority" document filed by Astellas, which establishes...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Beta
Ask a question!